A recent study in Paris brings good news to diabetic patients. Sirolimus-eluting Coronary Stent is a formidable treatment option for a broad range of patients, including diabetics who often are some of the most challenging patients with coronary artery disease to treat.
The six-month data from ECypher Registry, the world’s largest Internet-based post market surveillance study, highlights key areas of improvement including a dramatic number of diabetic patients that did not have to be retreated for coronary blockages.
While still enrolling, the registry currently is comprised of 12,180 patients who received the Johnson & Johnson Sirolimus-eluting Stent in 275 medical centers outside of the United States. Physicians conducted clinical follow-up and adjudication on more than 80 percent of the patient population in the study, providing further validity of the data.
"The results are encouraging and provide a much needed broader view of the efficacy of the Johnson & Johnson Sirolimus-eluting Stent in a range of lesion subsets and high risk patient populations," said Dr. Philip Urban, Director of Invasive Cardiology, La Tour Hospital in Geneva, Switzerland.
In the overall patient population, Dr. Urban reported a 2.5 percent Major Cardiac Adverse Event (MACE) rate, one percent Target Vessel Revascularization (TVR) rate that included angioplasty and by-pass surgery and a 0.3 percent Sub-acute Thrombosis (SAT) rate.
"The results from the diabetic subset are very encouraging given the excellent efficacy in the largest real world diabetic patient population," stated Dr. Dennis Donohoe, vice president, clinical and regulatory affairs, Cordis Corporation, a unit of Johnson & Johnson. "We continue to be encouraged by the strong performance of the Johnson & Johnson Sirolimus-eluting Stent in everyday clinical practice."
